CRYSTAL FORM S4 OF THE PLK4 INHIBITOR (1R,2S)-(E)-2-(3-(4-((CIS-2,6-DIMETHYLMORPHOLINO)METHYL)STYRYL)- 1 H-IMIDAZOL-6- YL)-5'-METHOXYSPIRO[CYCLOPROPANE-1,3'-INDOLIN]-2'-ONE FUMARATE

Title:

CRYSTAL FORM S4 OF THE PLK4 INHIBITOR (1R,2S)-(E)-2-(3-(4-((CIS-2,6-DIMETHYLMORPHOLINO)METHYL)STYRYL)- 1 H-IMIDAZOL-6- YL)-5'-METHOXYSPIRO[CYCLOPROPANE-1,3'-INDOLIN]-2'-ONE FUMARATE

Document Type and Number:

WIPO Patent Application WO/2020/215155

Kind Code:

A8

Abstract:

Disclosed is Crystal Form S4 of a fumarate salt of compound (I) represented by the following structural formula: (I) The molar ratio between compound (I) and fumaric acid is 1.0:1:0. Crystal Form S4, 5 characterized by an X-ray powder diffraction pattern which comprises peaks at 6.6°, 9.8°, 16.3°, 21.1°, 28.7°, and 30.2° ± 0.2 in 2θ.

Inventors:

LI SZE-WAN (CA)
BRAY MARK ROBERT (CA)

Application Number:

PCT/CA2020/050535

Publication Date:

November 26, 2020

Filing Date:

April 23, 2020

Export Citation:

Click for automatic bibliography generation Help

Assignee:

UNIV HEALTH NETWORK (CA)

International Classes:

C07D413/10; A61K31/191; A61K31/5377; A61P35/00; C07C57/15

Attorney, Agent or Firm:

BAKER, James et al. (CA)

Download PDF:

View/Download PDF PDF Help

Previous Patent: FAULT TOLERANT ROTATING ELECTRIC MACHINE

Next Patent: PRODRUGS OF A CDK INHIBITOR FOR TREATING CANCERS